Celularity Incorporated
Clinical trials sponsored by Celularity Incorporated, explained in plain language.
A clinical-stage biotechnology company developing allogeneic cell therapies from placental stem cells.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Cancer cell therapy trial for brain tumor withdrawn before starting
Disease control CancelledThis study planned to test a new treatment combining CYNK-001 (natural killer cells from donated cord blood) with interleukin-2 in adults whose glioblastoma had returned and could be surgically removed. The goal was to see if this combination was safe and could extend the time be…
Phase 1/2 • Sponsor: Celularity Incorporated • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Placenta cells aim to save limbs in diabetic foot ulcer trial
Disease control CancelledThis study tested whether injections of cells from donated placentas could improve blood flow and help heal foot ulcers in people with diabetes and blocked leg arteries. The trial planned to enroll about 24 adults with hard-to-heal foot sores. However, the study was withdrawn bef…
Phase 2 • Sponsor: Celularity Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC